參考文獻 |
[1] S. Jia, M. Shen, F. Zhang, and J. Xie, ”Recent advances in Momordica charantia: functional components and biological activities,” International journal of molecular sciences, vol. 18, no. 12, p. 2555, 2017.
[2] J. Grover and S. Yadav, ”Pharmacological actions and potential uses of Momordica charantia: a review,” Journal of ethnopharmacology, vol. 93, no. 1, pp. 123-132, 2004.
[3] T. Akihisa et al., ”Cucurbitane-type triterpenoids from the fruits of Momordica charantia and their cancer chemopreventive effects,” Journal of natural products, vol. 70, no. 8, pp. 1233-1239, 2007.
[4] J. Yue, J. Xu, J. Cao, X. Zhang, and Y. Zhao, ”Cucurbitane triterpenoids from Momordica charantia L. and their inhibitory activity against α-glucosidase, α-amylase and protein tyrosine phosphatase 1B (PTP1B),” Journal of Functional Foods, vol. 37, pp. 624-631, 2017.
[5] P. Khanna, S. Jain, A. Panagariya, and V. Dixit, ”Hypoglycemic activity of polypeptide-p from a plant source,” Journal of Natural Products, vol. 44, no. 6, pp. 648-655, 1981.
[6] A. P. Guevara, C. Y. Lim-Sylianco, F. M. Dayrit, and P. Finch, ”Acylglucosyl sterols from Momordica charantia,” Phytochemistry, vol. 28, no. 6, pp. 1721-1724, 1989.
[7] S. Begum, M. Ahmed, B. S. Siddiqui, A. Khan, Z. S. Saify, and M. Arif, ”Triterpenes, a sterol and a monocyclic alcohol from Momordica charantia,” Phytochemistry, vol. 44, no. 7, pp. 1313-1320, 1997.
[8] S.-J. Wu and L.-T. Ng, ”Antioxidant and free radical scavenging activities of wild bitter melon (Momordica charantia Linn. var. abbreviata Ser.) in Taiwan,” LWT-Food Science and Technology, vol. 41, no. 2, pp. 323-330, 2008.
[9] M. S. Akhtar, M. A. Athar, and M. Yaqub, ”Effect of Momordica charantia on blood glucose level of normal and alloxan-diabetic rabbits,” Planta Medica, vol. 42, no. 07, pp. 205-212, 1981.
[10] E. Karunanayake, J. Welihinda, S. Sirimanne, and G. S. Adorai, ”Oral hypoglycaemic activity of some medicinal plants of Sri Lanka,” Journal of ethnopharmacology, vol. 11, no. 2, pp. 223-231, 1984.
[11] B. S. Yadav, R. Yadav, R. B. Yadav, and M. Garg, ”Antioxidant activity of various extracts of selected gourd vegetables,” Journal of food science and technology, vol. 53, no. 4, pp. 1823-1833, 2016.
[12] A. Padmashree, G. K. Sharma, A. D. Semwal, and A. S. Bawa, ”Studies on the antioxygenic activity of bitter gourd (Momordica charantia) and its fractions using various in vitro models,” Journal of the Science of Food and Agriculture, vol. 91, no. 4, pp. 776-782, 2011.
[13] K. Mwambete, ”The in vitro antimicrobial activity of fruit and leaf crude extracts of Momordica charantia: a Tanzania medicinal plant,” African health sciences, vol. 9, no. 1, pp. 34-39, 2009.
[14] G. Leelaprakash, J. C. Rose, B. Gowtham, P. K. Javvaji, and S. Prasad, ”In vitro antimicrobial and antioxidant activity of Momordica charantia leaves,” Pharmacophore, vol. 2, no. 4, pp. 244-252, 2011.
[15] S. Mada, A. Garba, H. Mohammed, A. Muhammad, A. Olagunju, and A. Muhammad, ”Antimicrobial activity and phytochemical screening of aqueous and ethanol extracts of Momordica charantia L. leaves,” Journal of Medicinal Plants Research, vol. 7, no. 10, pp. 579-586, 2013.
[16] Q. Chen, L. L. Chan, and E. T. Li, ”Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet,” The Journal of nutrition, vol. 133, no. 4, pp. 1088-1093, 2003.
[17] Q. Chen and E. T. Li, ”Reduced adiposity in bitter melon (Momordica charantia) fed rats is associated with lower tissue triglyceride and higher plasma catecholamines,” British Journal of Nutrition, vol. 93, no. 5, pp. 747-754, 2005.
[18] E. F Fang and T. B Ng, ”Bitter gourd (Momordica charantia) is a cornucopia of health: a review of its credited antidiabetic, anti-HIV, and antitumor properties,” Current Molecular Medicine, vol. 11, no. 5, pp. 417-436, 2011.
[19] S. Desai and P. Tatke, ”Charantin: An important lead compound from Momordica charantia for the treatment of diabetes,” Journal of Pharmacognosy and Phytochemistry, vol. 3, no. 6, pp. 163-166, 2015.
[20] M. Lolitkar and M. R. Rao, ”Note on a hypoglycaemic principle isolated from the fruits of Momordica charantia,” Journal of the University of Bombay, vol. 29, pp. 223-224, 1962.
[21] D. M. Cuong et al., ”Accumulation of charantin and expression of triterpenoid biosynthesis genes in bitter melon (Momordica charantia),” Journal of agricultural and food chemistry, vol. 65, no. 33, pp. 7240-7249, 2017.
[22] J. Ahamad, S. R. Mir, and S. Amin, ”Antihyperglycamia activity of charantin isolated from fruits of Momordica Charantia Linn,” International Research Journal Of Pharmacy, vol. 10, pp. 61-64, 01/31 2019.
[23] S. Pugazhenthi and P. S. Murthy, ”Partial purification of a hypoglycemic fraction from the unripe fruits ofMomordica charantia Linn (bitter gourd),” Indian Journal of Clinical Biochemistry, vol. 10, no. 1, p. 19, 1995.
[24] A. Fuangchan et al., ”Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients,” Journal of ethnopharmacology, vol. 134, no. 2, pp. 422-428, 2011.
[25] J. Pitipanapong, S. Chitprasert, M. Goto, W. Jiratchariyakul, M. Sasaki, and A. Shotipruk, ”New approach for extraction of charantin from Momordica charantia with pressurized liquid extraction,” Separation and Purification Technology, vol. 52, no. 3, pp. 416-422, 2007.
[26] S. M. El-Said and A. S. Al-Barak, ”Extraction of insulin like compounds from bitter melon plants,” American Journal of Drug Discovery and Development, vol. 1, pp. 1-7, 2011.
[27] R. A. Moreau, B. D. Whitaker, and K. B. Hicks, ”Phytosterols, phytostanols, and their conjugates in foods: structural diversity, quantitative analysis, and health-promoting uses,” Progress in lipid research, vol. 41, no. 6, pp. 457-500, 2002.
[28] M. o. H. a. W. Health Promotion Administration, 2018.
[29] W. H. Organization, ”Diabetes,” 2018.
[30] M. A. Atkinson, G. S. Eisenbarth, and A. W. Michels, ”Type 1 diabetes,” The Lancet, vol. 383, no. 9911, pp. 69-82, 2014.
[31] B. B. Lowell and G. I. Shulman, ”Mitochondrial dysfunction and type 2 diabetes,” Science, vol. 307, no. 5708, pp. 384-387, 2005.
[32] C. Kim, K. M. Newton, and R. H. Knopp, ”Gestational diabetes and the incidence of type 2 diabetes: a systematic review,” Diabetes care, vol. 25, no. 10, pp. 1862-1868, 2002.
[33] J. K. DiStefano and R. M. Watanabe, ”Pharmacogenetics of anti-diabetes drugs,” Pharmaceuticals, vol. 3, no. 8, pp. 2610-2646, 2010.
[34] J.-L. Chiasson et al., ”Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial,” The Lancet, vol. 359, no. 9323, pp. 2072-2077, 2002.
[35] S. P. Clissold and C. Edwards, ”Acarbose,” Drugs, vol. 35, no. 3, pp. 214-243, 1988.
[36] P. Hollander, ”Safety profile of acarbose, an α-glucosidase inhibitor,” Drugs, vol. 44, no. 3, pp. 47-53, 1992.
[37] R. S. Hundal and S. E. Inzucchi, ”Metformin,” Drugs, vol. 63, no. 18, pp. 1879-1894, 2003.
[38] C. J. Bailey and R. C. Turner, ”Metformin,” New England Journal of Medicine, vol. 334, no. 9, pp. 574-579, 1996.
[39] N. Sturgess, D. Cook, M. J. Ashford, and C. N. Hales, ”The sulphonylurea receptor may be an ATP-sensitive potassium channel,” The Lancet, vol. 326, no. 8453, pp. 474-475, 1985.
[40] E. C. Chao and R. R. Henry, ”SGLT2 inhibition—a novel strategy for diabetes treatment,” Nature Reviews Drug Discovery, vol. 9, no. 7, pp. 551-559, 2010.
[41] N.-K. Lee and H.-D. Paik, ”Bioconversion using lactic acid bacteria: ginsenosides, GABA, and phenolic compounds,” J Microbiol Biotechnol, vol. 27, pp. 869-877, 2017.
[42] R. Di Cagno et al., ”Synthesis of γ-aminobutyric acid (GABA) by Lactobacillus plantarum DSM19463: functional grape must beverage and dermatological applications,” Applied microbiology and biotechnology, vol. 86, no. 2, pp. 731-741, 2010.
[43] J. E. Kim, J. S. Kim, Y. C. Song, J. Lee, and S. P. Lee, ”Novel bioconversion of sodium glutamate to γ-poly-glutamic acid and γ-amino butyric acid in a mixed fermentation using Bacillus subtilis HA and Lactobacillus plantarum K154,” Food Science and Biotechnology, vol. 23, no. 5, pp. 1551-1559, 2014.
[44] K. D. Setchell et al., ”Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability,” The American journal of clinical nutrition, vol. 76, no. 2, pp. 447-453, 2002.
[45] C. Rekha and G. Vijayalakshmi, ”Bioconversion of isoflavone glycosides to aglycones, mineral bioavailability and vitamin B complex in fermented soymilk by probiotic bacteria and yeast,” Journal of applied microbiology, vol. 109, no. 4, pp. 1198-1208, 2010.
[46] W. Suthanthangjai, P. Kilmartin, A. Phillips, K. Davies, and J. Ansell, ”Bioconversion of Pinot noir anthocyanins into bioactive phenolic compounds by lactic acid bacteria,” Nutrition and Aging, vol. 2, no. 2, 3, pp. 145-149, 2014.
[47] M. A. Huq, Y.-J. Kim, J.-W. Min, K. S. Bae, and D.-C. Yang, ”Use of Lactobacillus rossiae DC05 for bioconversion of the major ginsenosides Rb1 and Re into the pharmacologically active ginsenosides CK and Rg2,” Food Science and Biotechnology, vol. 23, no. 5, pp. 1561-1567, 2014.
[48] V. Sharma and H. Mishra, ”Fermentation of vegetable juice mixture by probiotic lactic acid bacteria,” Nutrafoods, vol. 12, no. 1, pp. 17-22, 2013.
[49] H. Gao et al., ”Momordica charantia juice with Lactobacillus plantarum fermentation: Chemical composition, antioxidant properties and aroma profile,” Food Bioscience, vol. 29, pp. 62-72, 2019.
[50] F. A. Mazlan, M. S. M. Annuar, and Y. Sharifuddin, ”Biotransformation of Momordica charantia fresh juice by Lactobacillus plantarum BET003 and its putative anti-diabetic potential,” PeerJ, vol. 3, p. e1376, 2015.
[51] G. L. Miller, ”Use of dinitrosalicylic acid reagent for determination of reducing sugar,” Analytical chemistry, vol. 31, no. 3, pp. 426-428, 1959.
[52] V. L. Singleton, R. Orthofer, and R. M. Lamuela-Raventós, ”[14] Analysis of total phenols and other oxidation substrates and antioxidants by means of folin-ciocalteu reagent,” in Methods in enzymology, vol. 299: Elsevier, 1999, pp. 152-178.
[53] 陳良宇 et al., ”鹼催化對 Folin-Ciocalteu 試劑檢測總多酚含量的影響,” MC-Transaction on Biotechnology, vol. 4, no. 1, pp. 10-19, 2012.
[54] C. M. Stoscheck, ”Quantitation of protein,” in Methods in enzymology, vol. 182: Elsevier, 1990, pp. 50-68.
[55] L. Chen et al., ”A turn-on resonance Raman scattering (BCS/Cu+) sensor for quantitative determination of proteins,” Applied spectroscopy, vol. 70, no. 2, pp. 355-362, 2016.
[56] P. Molyneux, ”The use of the stable free radical diphenylpicrylhydrazyl (DPPH) for estimating antioxidant activity,” Songklanakarin J. sci. technol, vol. 26, no. 2, pp. 211-219, 2004.
[57] S. J. Hossain, I. Tsujiyama, M. Takasugi, M. A. Islam, R. S. Biswas, and H. Aoshima, ”Total phenolic content, antioxidative, anti-amylase, anti-glucosidase, and antihistamine release activities of Bangladeshi fruits,” Food Science and Technology Research, vol. 14, no. 3, pp. 261-268, 2008.
[58] E. Apostolidis, Y.-I. Kwon, R. Ghaedian, and K. Shetty, ”Fermentation of milk and soymilk by Lactobacillus bulgaricus and Lactobacillus acidophilus enhances functionality for potential dietary management of hyperglycemia and hypertension,” Food biotechnology, vol. 21, no. 3, pp. 217-236, 2007.
[59] P. P. McCue and K. Shetty, ”Phenolic antioxidant mobilization during yogurt production from soymilk using Kefir cultures,” Process Biochemistry, vol. 40, no. 5, pp. 1791-1797, 2005. |